These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2187525)

  • 21. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
    Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
    Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis.
    Mahner S; Oskay-Özcelik G; Heidrich-Lorsbach E; Fuxius S; Sommer H; Klare P; Belau A; Ruhmland B; Heuser T; Kölbl H; Markmann S; Sehouli J
    J Cancer Res Clin Oncol; 2012 Aug; 138(8):1413-9. PubMed ID: 22526159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation.
    Bojko P; Hilger RA; Ruehm SG; Dirsch O; Seeber S; Scheulen ME
    Bone Marrow Transplant; 2003 Mar; 31(6):487-91. PubMed ID: 12665845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
    Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
    Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treosulfan in the treatment of metastatic melanoma: from chemosensitivity testing to clinical trials.
    Neuber K
    Recent Results Cancer Res; 2003; 161():159-79. PubMed ID: 12528807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
    Markman M; Bundy BN; Alberts DS; Fowler JM; Clark-Pearson DL; Carson LF; Wadler S; Sickel J
    J Clin Oncol; 2001 Feb; 19(4):1001-7. PubMed ID: 11181662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effectiveness of cisplatin alone and in combination within the scope of primary therapy of ovarian cancer. Results of a prospective multicenter study].
    Richter P; Krafft W; Müller U; Brückmann D; Homann S; König EM; Lotze P; Morack G; Neubert S; Nöschel H
    Zentralbl Gynakol; 1990; 112(7):421-9. PubMed ID: 1695049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treosulfan as an effective second-line therapy in ovarian cancer.
    Gropp M; Meier W; Hepp H
    Gynecol Oncol; 1998 Oct; 71(1):94-8. PubMed ID: 9784326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma.
    O'Neill PA; Butt M; Eswar CV; Gillis P; Marshall E
    Melanoma Res; 2006 Jun; 16(3):245-8. PubMed ID: 16718271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.
    Lévi F; Benavides M; Chevelle C; Le Saunier F; Bailleul F; Misset JL; Regensberg C; Vannetzel JM; Reinberg A; Mathé G
    J Clin Oncol; 1990 Apr; 8(4):705-14. PubMed ID: 2179481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
    Rothenberg ML; Liu PY; Braly PS; Wilczynski SP; Hannigan EV; Wadler S; Stuart G; Jiang C; Markman M; Alberts DS
    J Clin Oncol; 2003 Apr; 21(7):1313-9. PubMed ID: 12663720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation.
    Shimoni A; Labopin M; Savani B; Hamladji RM; Beelen D; Mufti G; Socié G; Delage J; Blaise D; Chevallier P; Forcade E; Deconinck E; Mohty M; Nagler A
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):751-757. PubMed ID: 29247780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage III and IV patients].
    Salzer H; Gitsch E; Dittrich C; Sevelda P; Karrer K; Schemper M; Stempel-Smekal G; Langer M; Wagner G; Rainer H
    Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):761-8. PubMed ID: 3908214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
    Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
    Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
    Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
    Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma.
    Schmittel A; Schuster R; Bechrakis NE; Siehl JM; Foerster MH; Thiel E; Keilholz U
    Melanoma Res; 2005 Oct; 15(5):447-51. PubMed ID: 16179873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL).
    Fichtner I; Becker M; Baumgart J
    Eur J Cancer; 2003 Apr; 39(6):801-7. PubMed ID: 12651206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study.
    Spieth K; Kaufmann R; Gille J
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):377-82. PubMed ID: 12879280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer.
    Hilger RA; Jacek G; Oberhoff C; Kredtke S; Baumgart J; Seeber S; Scheulen ME
    Cancer Chemother Pharmacol; 2000; 45(6):483-8. PubMed ID: 10854136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.